These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28659039)

  • 1. ADHD Medication and Substance-Related Problems.
    Quinn PD; Chang Z; Hur K; Gibbons RD; Lahey BB; Rickert ME; Sjölander A; Lichtenstein P; Larsson H; D'Onofrio BM
    Am J Psychiatry; 2017 Sep; 174(9):877-885. PubMed ID: 28659039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study.
    McCabe SE; Dickinson K; West BT; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2016 Jun; 55(6):479-86. PubMed ID: 27238066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes.
    Chang Z; Quinn PD; Hur K; Gibbons RD; Sjölander A; Larsson H; D'Onofrio BM
    JAMA Psychiatry; 2017 Jun; 74(6):597-603. PubMed ID: 28492937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of and Factors Associated With Long-term Concurrent Use of Stimulants and Opioids Among Adults With Attention-Deficit/Hyperactivity Disorder.
    Wei YJ; Zhu Y; Liu W; Bussing R; Winterstein AG
    JAMA Netw Open; 2018 Aug; 1(4):e181152. PubMed ID: 30646105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.
    Molina BS; Hinshaw SP; Eugene Arnold L; Swanson JM; Pelham WE; Hechtman L; Hoza B; Epstein JN; Wigal T; Abikoff HB; Greenhill LL; Jensen PS; Wells KC; Vitiello B; Gibbons RD; Howard A; Houck PR; Hur K; Lu B; Marcus S;
    J Am Acad Child Adolesc Psychiatry; 2013 Mar; 52(3):250-63. PubMed ID: 23452682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
    Kollins SH
    Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Suicide Attempts.
    Chang Z; Quinn PD; O'Reilly L; Sjölander A; Hur K; Gibbons R; Larsson H; D'Onofrio BM
    Biol Psychiatry; 2020 Sep; 88(6):452-458. PubMed ID: 31987492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychostimulants/Atomoxetine and Serious Cardiovascular Events in Children with ADHD or Autism Spectrum Disorder.
    Houghton R; de Vries F; Loss G
    CNS Drugs; 2020 Jan; 34(1):93-101. PubMed ID: 31768949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
    CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature.
    Wilens TE; Faraone SV; Biederman J; Gunawardene S
    Pediatrics; 2003 Jan; 111(1):179-85. PubMed ID: 12509574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature.
    Barkla XM; McArdle PA; Newbury-Birch D
    BMC Psychiatry; 2015 Oct; 15():270. PubMed ID: 26517983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulant ADHD medication and risk for substance abuse.
    Chang Z; Lichtenstein P; Halldner L; D'Onofrio B; Serlachius E; Fazel S; Långström N; Larsson H
    J Child Psychol Psychiatry; 2014 Aug; 55(8):878-85. PubMed ID: 25158998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV; Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.
    Perugi G; Vannucchi G
    Expert Opin Pharmacother; 2015; 16(14):2193-204. PubMed ID: 26364896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
    Biederman J
    J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study.
    Dalsgaard S; Mortensen PB; Frydenberg M; Thomsen PH
    Addict Behav; 2014 Jan; 39(1):325-8. PubMed ID: 24090624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does stimulant treatment lead to substance use disorders?
    Faraone SV; Wilens T
    J Clin Psychiatry; 2003; 64 Suppl 11():9-13. PubMed ID: 14529324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Injury According to Attention Deficit Hyperactivity Disorder, Comorbid Mental Illness, and Medication Therapy.
    Merrill RM; Thygerson SM; Palmer CA
    Pharmacopsychiatry; 2016 Mar; 49(2):45-50. PubMed ID: 26829453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Depression: A Nationwide Longitudinal Cohort Study.
    Chang Z; D'Onofrio BM; Quinn PD; Lichtenstein P; Larsson H
    Biol Psychiatry; 2016 Dec; 80(12):916-922. PubMed ID: 27086545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database.
    McAfee AT; Holdridge KC; Johannes CB; Hornbuckle K; Walker AM
    Curr Drug Saf; 2008 May; 3(2):123-31. PubMed ID: 18690990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.